Ignite Creation Date:
2024-05-06 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06171984
Status:
RECRUITING
Last Update Posted:
2023-12-15
First Post:
2022-09-06
Brief Title:
Thrombophilia Assessment Under DOAC Effectiveness of Activated Charcoal
Sponsor:
University Hospital Strasbourg France
Organization:
University Hospital Strasbourg France
Study Overview
Official Title:
Thrombophilia Assessment Under Direct Oral Anticoagulants DOAC Efficacy of Activated Charcoal
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DOAC-Stop
Brief Summary:
Direct oral anticoagulants DOAC are anticoagulant molecules that act either directly on factor Xa Apixaban Rivaroxaban or on factor IIa Dabigatran
AODs interfere with most coagulation tests especially those performed by chronometric technique
For this reason part of the thrombophilia workup protein S search for lupus anticoagulants antithrombin for patients on dabigatran cannot be performed on DOACs at the HUS
Recent studies have highlighted the effectiveness of activated charcoal to adsorb DOACs in order to perform certain hemostasis tests
AODs interfere with most coagulation tests especially those performed by chronometric technique
For this reason part of the thrombophilia workup protein S search for lupus anticoagulants antithrombin for patients on dabigatran cannot be performed on DOACs at the HUS
Recent studies have highlighted the effectiveness of activated charcoal to adsorb DOACs in order to perform certain hemostasis tests
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None